Research Analysts’ Weekly Ratings Updates for Harvard Bioscience (HBIO)

Harvard Bioscience (NASDAQ: HBIO) recently received a number of ratings updates from brokerages and research firms:

• 12/2/2025 – Harvard Bioscience had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/26/2025 – Harvard Bioscience had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/20/2025 – Harvard Bioscience had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/17/2025 – Harvard Bioscience was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 11/9/2025 – Harvard Bioscience was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 11/1/2025 – Harvard Bioscience was upgraded by analysts at Wall Street Zen to a “buy” rating.
• 10/8/2025 – Harvard Bioscience had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.